Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotech (PBYI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Why Puma Biotechnology Is Soaring Today | The Motley Fool
PBYI | Puma Biotechnology Inc. Stock Overview (U.S.: Nasdaq) | Barron's
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) Stock Price, News & Info | The Motley Fool
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib - September 21, 2022 - Zacks.com
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
PBYI | Puma Biotechnology Inc. Stock Overview (U.S.: Nasdaq) | Barron's
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Stock (NASDAQ:PBYI), Quotes and News Summary - Benzinga
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
2 Drug Stocks Near Key Technical Levels After ASCO
Puma Biotechnology (NasdaqGS:PBYI) Stock Price & Quote Analysis - Simply Wall St
Puma Biotechnology
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology: Increasing Our Exposure (NASDAQ:PBYI) | Seeking Alpha
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology (PBYI) Stock Price, News & Info | The Motley Fool
Puma Biotechnology
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology
